VYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligo
US-based pharmaceutical company VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel, known as repibresib, for treating non-segmental vitiligo. The double-blind, vehicle-controlled study is assessing the safety …